Although prospective, longitudinal studies are needed, we propose that patients with SSc who exhibit an imbalance between NO and ET-1 production and who have a short length of CCTTT repeat of the NOS2 gene can be treated with a phosphodiesterase type 5 inhibitor before the occurrence of PAH. This evidence concerns the gene EDN1 and pulmonary arterial hypertension.